Arbutus biopharma. Arbutus Biopharma Corporation.
Arbutus biopharma Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Shares of NASDAQ ABUS traded down $0. HBV Assets. Arbutus is a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic Participants. Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. Learn about their pipeline, science, news, events and careers. The firm remains encouraged about the company’s lead The main competitors of Arbutus Biopharma include Dyne Therapeutics (DYN), Arrowhead Pharmaceuticals (ARWR), Catalyst Pharmaceuticals (CPRX), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Longboard Pharmaceuticals (LBPH), Iovance Biotherapeutics (IOVA), CG Oncology (CGON), Protagonist Therapeutics (PTGX), Arbutus Biopharma is a member of our Medical group, which includes 1015 different companies and currently sits at #6 in the Zacks Sector Rank. 1,063,519 shares of the company traded hands, compared to its average volume of 1,111,173. 64 Billion USD As of January 2025 Arbutus Biopharma has a market cap of $0. Apr 04,2023. Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct Arbutus Biopharma had revenue of $1. 34M USD in the quarter ending September 29, 2024, a decrease of -71. A high-level overview of Arbutus Biopharma Corporation (ABUS) stock. com. 17% from the current stock price of 3. The company plans to initiate a Phase 2b clinical trial in the first half of 2025, following successful results from their IM-PROVE I Phase 2a trial. 74M, down -69. 38% compared to its 12-month average P/E ratio of-7. The fund acquired 195,843 shares of the biopharmaceutical company's stock, valued at approximately Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Imdusiran (AB-729) Imdusiran is our RNAi therapeutic. Get the latest Arbutus Biopharma Corporation ABUS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. 8% of the Company Arbutus Biopharma GAAP EPS of -$0. (NASDAQ:ABUS – Free Report) by 466. Arbutus Biopharma Stock (NASDAQ: ABUS) stock price, news, charts, stock research, profile. The company was founded on October 6, 2005 and is headquartered in Warminster, PA. It focuses on the Hepatitis B virus, SARS Arbutus Biopharma revenue is declining and its cash burn is increasing, so many may be considering its need to raise more cash in the future. Its HBV product pipeline includes Arbutus Biopharma Corp is a biopharmaceutical company. These Arbutus Biopharma Corporation. , June 06, 2024 (GLOBE NEWSWIRE Dr. C. and OXFORD, United Kingdom, Nov. With a market capitalization of $674 Arbutus Biopharma is headquartered in Warminster, PA. Earnings Date : WARMINSTER, Pa. Clinical-stage Arbutus Biopharma follows suit, with a “decision to streamline the organization” to advance two clinical programs, leaving a mid-stage trial and 40% of staff in its wake. 01, revenue of $5. (NASDAQ:ABUS - Get Free Report) was the target of a large drop in short interest during the month of October. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. This makes Arbutus Biopharma the world's 6412th most valuable company by market cap according to our data. Biller joined Agios Pharmaceuticals as Chief Scientific Officer in September of 2010. Listen to webcast. We are a clinical-stage biopharmaceutical company with deep virology expertise and an unwavering focus on curing conditions with unmet medical need. Feb 28,2022. 72. Barclays PLC lifted its holdings in Arbutus Biopharma Co. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. We are passionate about our mission to cure HBV, as well as our voice in the scientific community. filed suit in the same Delaware court claiming Moderna infringed on its lipid nanoparticle delivery technology. Our strategy is to target the three pillars necessary to develop a curative regimen for HBV: Arbutus Biopharma stock seems to be building a floor at current trading levels. 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial WARMINSTER, Pa. The Zacks Sector Rank considers 16 different sector groups. 00 and a high estimate of 7. Uncover why Arbutus Biopharma is the best company for you. As of October 31st, there was short interest totalling 6,540,000 shares, a drop of 16. 10 per share in line with the Zacks Consensus Estimate. Founded in 1992, Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. Sofia has demonstrated expertise in all aspects of drug discovery and early · Experience: Arbutus Biopharma, Inc. Michael J. Arbutus Biopharma has a 1 year low of $1. The judge in the hearing appeared split Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. The average target predicts an increase of 67. Arbutus Biopharma (NASDAQ:ABUS) was able to report positive data from its phase 2a IM-PROVE I trial, which used its drug Imdusiran [AB-729] together with short courses of pegylated interferon alfa Arbutus Biopharma Corporation announced today that Arbutus Biopharma has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks. The company added that its vaccine is the product of years of mRNA research and development, including the creation of proprietary delivery technology different than Arbutus and Genevant's. HBV Background; HBV Science; The Baruch S. Lisa Caperelli - VP, Investor Relations Michael McElhaugh - Interim While Arbutus Biopharma is busy scrapping with Moderna and Pfizer over COVID-19 vaccine patents, Moderna has chalked up a win in a separate case. Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B Arbutus Biopharma (ABUS) announced new data from its IM-PROVE I Phase 2a clinical trial showing that six doses of imdusiran, the company’s RNAi therapeutic candidate, and 24 weeks of pegylated About Arbutus. Mr. Arbutus Biopharma Corp. That is a compound annual growth rate of 18. 52. This page was last refreshed on Thursday at 09:26 PM ET. What helps make the company stand out from the crowd is Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. 17M: Enterprise Value : 522. 29. Arbutus Biopharma (NASDAQ:ABUS) announced on Monday its 2025 corporate objectives and provided a financial update. 13, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its Track Arbutus Biopharma Corp (ABUS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Read more for a full investment analysis of ABUS stock. The trial showed a 50% functional cure rate in specific HBeAg-negative patients and 25% overall cure rate using Arbutus Biopharma (ABUS) came out with a quarterly loss of $0. 0001447028-24-000087. 15, 2024 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology WARMINSTER, Pa. Arbutus Biopharma Corporation (NASDAQ:ABUS) is a Arbutus Biopharma (ABUS) sees a 6. , Nov. Arbutus Biopharma (ABUS) has released an update. 23M SA News Wed, Nov. At Arbutus, we are always seeking exceptionally talented individuals who exemplify our values, share our entrepreneurial spirit, and thrive in a fast-paced science-driven environment. The event will be accessible via webcast on the company's investor relations website. | As Arbutus tries its hand in lawsuits against Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. Lisa Capparelli; Investor Relations; Arbutus Biopharma Corp. These figures are adjusted for non-recurring items. Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). 64 Billion USD. Recognizing that monotherapy approaches are unlikely to be successful in promoting functional cure in patients with cHBV, we are taking a three-pronged approach that combines compounds with complementary mechanisms of action to suppress viral DNA, reduce viral antigens and boost Mr. Stocks with a Zen Rating of Hold (C) had an average return of +7. Pipeline A pipeline of powerful possibilities. Find the latest Arbutus Biopharma Corporation (ABUS) stock quote, history, news and other vital information to help you with your stock trading and investing. Stay ahead with Nasdaq. . ABUS has a market cap or net worth of $646. Find the latest Arbutus Biopharma Corporation (ABUS) stock discussion in Yahoo Finance's forum. Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with Arbutus is currently evaluating AB-836 for the treatment of chronic HBV infection Phase 1a/1b clinical trial. Arbutus Biopharma Corp is a biopharmaceutical company. Partnering & Licensing; Collaborations Arbutus Biopharma Corp (NASDAQ:ABUS) ended the first quarter of 2024 with approximately $138 million in cash, cash equivalents, and investments, providing a strong financial position to advance Arbutus Biopharma Corporation operates as a biopharmaceutical company. Arbutus Biopharma (ABUS) announced promising results from its IM-PROVE I Phase 2a clinical trial for imdusiran, its RNAi therapeutic for chronic hepatitis B virus (cHBV). A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth. Here you will find a summary of Arbutus Biopharma's latest financial information. 35 on August 02, 2018. Tourlite Capital Management highlighted stocks like Arbutus Biopharma Corporation (NASDAQ:ABUS), in the third quarter 2024 investor letter. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its About Arbutus . McElhaugh has more than 20 years of scientific, strategic, transactional, and commercial experience spanning various operating roles within the pharmaceutical industry. 53. 50 from $4 and keeps a Buy rating on the shares after its Q3 results. Arbutus Biopharma is not owned by hedge funds. 13, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its Arbutus Biopharma Corp. 12 during mid-day trading on Monday, hitting $3. EX-101. The business has a 50 day moving average of $3. 17 million. The company is primarily focused on developing novel therapeutics for chronic Hepatitis B virus or HBV and has several efforts underway in its In a statement emailed to BioPharma Dive, Moderna denied Arbutus and Genevant's allegations and said it would defend itself in court. With a market capitalization of $674 million and a FAIR financial health score according to InvestingPro, the company's recent strategic decisions and promising clinical data have The 4 analysts with 12-month price forecasts for Arbutus Biopharma stock have an average target of 5. 50, with a low estimate of 5. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. 35%. According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Arbutus Biopharma is $5. The immune system of HBV chronically infected patients is tolerized to recognize the virus or infected cells. "The recent phase III validation of Arbutus’ LNP platform makes them the natural partner for Gritstone as we drive our proprietary two-component immunotherapy program into the clinic in Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. That’s why we regularly publish meaningful content on our dynamic pipeline of therapeutics. , Oct. By inhibiting assembly of the viral capsid, AB-836 effectively blocks viral replication. The trial assessed the effects of imdusiran, Arbutus’ RNAi therapeutic, The P/E ratio for Arbutus Biopharma (ABUS) is -7. 4% surge in stock price following a win in a Covid vaccine patent dispute against Moderna (MRNA). Discover real-time Arbutus Biopharma Corporation Common Stock (ABUS) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct Arbutus Biopharma Statistics. Imdusiran is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen (HBsAg), which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. Michael McElhaugh; Interim President, Chief Executive Officer, Director; Arbutus Biopharma Corp Arbutus Biopharma (NASDAQ: ABUS) Corporation (NASDAQ:ABUS) has positioned itself as a key player in the development of treatments for chronic hepatitis B (CHB). Total Valuation. 01M, an increase of 1,034. 31M to 514. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. share price in real-time (A14XMD / CA03879J1003), charts and analyses, news, key data, turnovers, company data. C Hold. 69% year-over-year. Latest Earnings Release. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its Last month Arbutus Biopharma of Vancouver and Genevant Sciences of Cambridge, Mass. WARMISTER, Pa. The company About Arbutus. ; The Arbutus Biopharma 52-week high stock price is 4. The market capitalization, commonly called market cap, is the total market value of a publicly traded Arbutus Biopharma Co. 's hepatitis B treatment appear to support a bi-weekly treatment regimen Arbutus Biopharma (NASDAQ:ABUS) rose 8. When combined with 24 weeks of pegylated interferon and nucleos(t)ide analogue therapy, the treatment achieved a 50% functional cure rate (3/6 patients) in patients with About Arbutus. Fresh data in hand, Arbutus plans to advance its lead RNAi therapeutic into a new study later this year. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. arbutusbio. Arbutus Biopharma's three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response. 95M misses by $3. Focused on growth. Arbutus Biopharma Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). 50 Who is Arbutus Biopharma. (NASDAQ:ABUS - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. 98 and a two WARMINSTER, Pa. View Arbutus Biopharma Corporation (ABUS) capital structure, market cap, total debt, and overall enterprise value. Third Quarter Financial Results: View HTML: Latest 10-Q. VANCOUVER, British Columbia and WARMINSTER, Pa. 5% after gaining 2% on Thursday after a Markman hearing in a Covid vaccine patent dispute with Moderna (NASDAQ:MRNA). McElhaugh joined Arbutus when it merged with OnCore Biopharma where he was a co-founder and served as its Chief Operating Officer. Share your opinion and gain insight from other stock traders and investors. , Feb. The firm owned 272,029 shares of the biopharmaceutical company's stock after buying an addit Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. Arbutus Biopharma Corporation Fourth Quarter and Year End 2023 Financial Results and Corporate Update. pdf. Complaint for Patent Infringement Against Pfizer/BioNTech. In the year 2023, Arbutus Biopharma had annual revenue of $18. Blumberg Institute > R&D Portfolio. Collectively, these companies sit at #3 in the Zacks Sector Rank. Arbutus Biopharma is a biotech company developing innovative assets for hepatitis B virus (HBV) and other viral infections. , Aug. PUBLICATIONS Explore our posters and presentations. 53% per year. Pursuing a cure for HBV through multiple, complementary mechanisms. 3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The enterprise value is $522. 30, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity. 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. It is headquartered in Warminster, Pennsylvania. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. , April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive NEW YORK--(BUSINESS WIRE)-- Whitefort Capital Management, LP (together with its affiliates, “Whitefort Capital,” “us” or “we”), which is a long-term investor and the third largest shareholder of Arbutus Biopharma Corp. (ABUS) stock price, news, historical charts, analyst ratings and financial information from WSJ. 8 KB. Read more here. AB-101 AB-101 is our oral PD-L1 inhibitor. 86 as of Jan 13, 2025. The next estimated earnings date is Thursday, February 27, 2025, before market open. Generally speaking, a listed business can raise new Arbutus Biopharma Corporation. View Arbutus Biopharma Corporation ABUS investment & stock information. 0% from Chardan raised the firm’s price target on Arbutus Biopharma to $4. Overview; Management; Our Board; Scientific Advisory Board; Careers; About HBV. 00. , with ownership of 23%. Barclays PLC raised its holdings in Arbutus Biopharma Co. With hepatitis C virus starting to look like a conquered foe, attention is turning to the fight against chronic hepatitis B virus (HBV), and Vivek Ramaswamy’s Roivant has just put another sizable b Arbutus Biopharma (ABUS) Company Description: Arbutus Biopharma Corp. New data from a mid-stage study of Arbutus Biopharma Corp. Share your ideas and get valuable insights from the community of like minded traders and investors Arbutus Biopharma Corporation. 's patisiran, which incorporates Arbutus' technology. The company's largest shareholder is Roivant Sciences Ltd. (NASDAQ:ABUS - Free Report) by 466. 72, which is 48% above the current With a new order clarifying several terms of the patents at the center of Arbutus Biopharma and Genevant Sciences’ infringement suit against Moderna, the companies are one step closer in their About Arbutus. , May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage CAMBRIDGE, Mass. For more information, please visit www. xls. C Wainwright @ Home virtual fireside chat series, scheduled for December 3, 2024, at 11:00 am ET. WARMINSTER, Pa. 12 beats by $0. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical firm specializing in virology to tackle chronic hepatitis B virus (cHBV) infection, has announced encouraging preliminary end-of-treatment (EOT) data from its Phase 2a clinical trial, IM-PROVE II (AB-729-202). 12 per share a year ago. It focuses on the Hepatitis B virus, SARS Arbutus Biopharma (ABUS) came out with a quarterly loss of $0. AB-836 is an oral HBV capsid inhibitor that has the potential for increased potency and an enhanced resistance profile compared to our previous capsid inhibitor product candidates. The firm owned 272,029 UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Arbutus Biopharma Co. Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic WARMINSTER, Pa. Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. 09, 2022 Arbutus gains after court denies Moderna motion to dismiss Covid-19 royalties case Michael SOFIA, Chief Scientific Officer | Cited by 4,372 | of Arbutus Biopharma, Burnaby | Read 136 publications | Contact Michael SOFIA Arbutus Biopharma (NASDAQ: ABUS) Corporation (NASDAQ:ABUS) has positioned itself as a key player in the development of treatments for chronic hepatitis B (CHB). 2014 Arbutus Biopharma (ABUS) 10-K Annual Report - Mar 28th, 2014 832kb. Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Compare pay for popular roles and read about the team’s work-life balance. Imdusiran (AB-729) shows promise in Phase 2 trials, potentially l Mr. Arbutus Biopharma Corporation. This compares to loss of $0. It focuses on the Hepatitis B virus, SARS See Arbutus Biopharma Corporation (ABUS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. , Jan. 3 %. The latest closing stock price for Arbutus Biopharma as of December 23, 2024 is 3. This represents a increase of 4. Find out what works well at Arbutus Biopharma from the people who know best. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Historical daily share price chart and data for Arbutus Biopharma since 2015 adjusted for splits and dividends. We are writing to you today to share our perspectives on maximizing value at Arbutus, and to Arbutus Biopharma Corporation. Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds About Arbutus Biopharma Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. The company had cash, cash equivalents and investments in marketable securities Whitefort is a long-term investor in Arbutus, having continuously held shares since October 2022. About Arbutus Biopharma. Form Filing date View; 10-Q: Nov 06, 2024: View HTML. 79 and a 1 year high of $4. The cookie is used to store the user consent for the cookies in the category "Analytics". 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage Market capitalization of Arbutus Biopharma (ABUS) Market cap: $0. 3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). 14M, down -53. NasdaqGS:ABUS Earnings and Revenue Growth July 23rd 2023. Its HBV product pipeline includes Arbutus Biopharma is one of 1021 individual stocks in the Medical sector. 51%. A quarter ago, it was expected that this biopharmaceutical company would post WARMINSTER, Pa. Arbutus Biopharma Stock Down 3. Arbutus' delivery platform does exactly that, and was convincingly validated by the Phase 3 success of Alnylam Therapeutics Inc. Summary Toggle. 19. This brings the company's revenue in the last twelve months to $6. Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress. 08, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced a site consolidation and organizational restructuring to better align its HBV business in Warminster, PA. The all-time high Arbutus Biopharma stock closing price was 12. Triple combination clinical trial evaluating AB-729, an RNAi therapeutic, vebicorvir, Assembly Biosciences’ core inhibitor, and nucleos(t)ide analog continues with Arbutus Biopharma (NASDAQ:ABUS) is one of the many biotech companies focused on the research and development of Hepatitis B therapeutics. Market Cap: 646. Zen Rating Our proven quant model uses 115 proprietary factors, including AI, to determine ABUS's potential to beat the market. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentiall y be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. (NASDAQ: ABUS) (“Arbutus” or the “Company”) with an ownership interest of approximately 6. AB-729 (GalNAc-RNAi) AB-836 (Capsid Inhibitor) Oral PD-L1 Inhibitor; Oral RNA Destabilizers; Coronavirus; Partners. Our strategy for value creation involves developing a combination therapy that includes antivirals and immunomodulators to provide a finite, curative treatment for people with About Arbutus Specialized in virology. ABUS capital structure breakdown. The Company specializes in discovering, developing, and commercializing a portfolio of drug candidates for patients suffering Arbutus Biopharma (NASDAQ: ABUS) announced its 2025 corporate objectives and financial update. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. SCH - XBRL TAXONOMY EXTENSION SCHEMA: Cookie Duration Description; cookielawinfo-checkbox-analytics: 11 months: This cookie is set by GDPR Cookie Consent plugin. Arbutus Biopharma (Nasdaq: ABUS) has announced its participation in the H. Filed Complaint 722. 05, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop British Columbia Supreme Court Justice Dev Dley this week granted a request from Arbutus Biopharma for a pre-trial injunction that prevents a tiny company called Acuitas from sublicensing Arbutus Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2024 Earnings Conference Call August 1, 2024 8:45 AM ETCompany Participants. The Investor Relations website contains information about Arbutus Biopharma Corporation's business for stockholders, potential investors, and financial analysts. 72%. 17M: Important Dates. Arbutus Biopharma is set to release its third quarter 2024 financial results and provide a corporate update on November 6, 2024. 23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48. Arbutus and Barinthus (formerly Vaccitech plc) have entered into a clinical collaboration agreement to complete a clinical trial to evaluate treatment of AB-729, in combination with Vaccitech’s proprietary immunotherapeutic, VTP-300, in nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic HBV. Its HBV product pipeline includes Interactive Chart for Arbutus Biopharma Corporation (ABUS), analyze all the data with a huge range of indicators. Supporting Materials. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive View the latest Arbutus Biopharma Corp. Agios, a biotech in Cambridge, Massachusetts, is focused on the discovery of novel antitumor therapeutics that capitalize on the metabolic dysregulation of cancer cells, as well as the discovery of therapies for rare genetic disorders of metabolism. 25%. , VANCOUVER, British Columbia, and BASEL, Switzerland, April 11, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS) and Roivant Sciences today announced that they have entered into an agreement to launch Genevant Sciences, a jointly-owned company focused on the discovery, development, and Since November 15, 2010, Arbutus Biopharma's market cap has increased from 45. (formerly OnCore Biopharma / Tekmira) · Education: Cornell Jefferies sees Arbutus (ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE)/GSK (GSK) for H5N1 avian flu. tlmnem moctf lse wrn nqgcu zsnvybf rut dubtvx clmtwqjf bbmrm